Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide

Clinical and Experimental Metastasis

Volumn 30, Issue 2, 2013, Pages 119-132

  Newton Northup, Jessica R ^a   Dickerson, Marie T ^a   Ma, Lixin ^a   Besch Williford, Cynthia L ^b   Deutscher, Susan L ^a,c  

^a University of Missouri   (United States)

^b IDEXX RADIL Lab Animal Diagnostics and Biological Materials Testing   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Galectin 3; In vivo peptide therapy; MDA MB 231 breast carcinoma; Metastasis inhibition; Tumor targeting peptides

Indexed keywords

ANTIMETASTATIC AGENT; G3 C12 PEPTIDE; GALECTIN 3; POLYPEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; LUCIFERASE; PEPTIDE FRAGMENT; THOMSEN FRIEDENREICH ANTIGEN; THOMSEN-FRIEDENREICH ANTIGEN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL ADHESION; CELL CULTURE; CONTROLLED STUDY; DRUG PROTEIN BINDING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LUNG PARENCHYMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PHAGE DISPLAY; TUMOR VOLUME; ANIMAL; BACTERIOPHAGE; BREAST TUMOR; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FEMALE; IMMUNOLOGY; LUNG TUMOR; METABOLISM; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PATHOLOGY; PEPTIDE LIBRARY; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BACTERIOPHAGES; BREAST NEOPLASMS; CELL ADHESION; FEMALE; GALECTIN 3; HUMANS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84875082168     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9516-y     Document Type: Article

References (56)

1. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM (2010) Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 176(5):2067-2081. doi: 10.2353/ajpath.2010.090353
2. Sakaki M, Fukumori T, Fukawa T, Elsamman E, Shiirevnyamba A, Nakatsuji H, Kanayama HO (2010) Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 57(1-2):152-157. doi: JST.JSTAGE/jmi/57.152
3. Saussez S, Camby I, Toubeau G, Kiss R (2007) Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 29(9):874-884. doi: 10.1002/hed.20559
4. Stewart CJ, Crook ML (2010) Galectin-3 expression in uterine endometrioid adenocarcinoma: comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion. Int J Gynecol Pathol 29(6):555-561. doi: 10.1097/PGP.0b013e3181e4ee4ea
5. Turkoz HK, Oksuz H, Yurdakul Z, Ozcan D (2008) Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 19(2):92-96. doi: 10.1007/s12022-008-9033-3
6. Baptiste TA, James A, Saria M, Ochieng J (2007) Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp Cell Res 313(4):652-664. doi: 10.1016/j.yexcr.2006.11.005
7. Shalom-Feuerstein R, Cooks T, Raz A, Kloog Y (2005) Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 65(16):7292-7300. doi: 10.1158/0008-5472.CAN-05-0775
8. Moisa A, Fritz P, Eck A, Wehner HD, Murdter T, Simon W, Gabius HJ (2007) Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res 27(4B):2131-2139
9. Kumar SR, Deutscher SL (2008) 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. J Nucl Med 49(5):796-803. doi: 10.2967/jnumed.107.048751
10. Koo JS, Jung W (2011) Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J 52(1):89-97. doi: 10.3349/ymj.2011.52.1.89
11. Mazurek N, Sun YJ, Liu KF, Gilcrease MZ, Schober W, Nangia-Makker P, Raz A, Bresalier RS (2007) Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J Biol Chem 282(29):21337-21348. doi: 10.1074/jbc.M608810200
12. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, Quinn TP (2001) The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61:4851-4857
13. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899-909
14. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, Malorni W, Iacobelli S (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85:545-554
15. Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL (2005) Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 26:309-318
16. Springer GF (1984) T and Tn, general carcinoma autoantigens. Science 224(4654):1198-1206
17. Bresalier RS, Byrd JC, Wang L, Raz A (1996) Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. Cancer Res 56:4354-4357
18. Peletskaya EN, Glinsky VV, Glinsky GV, Deutscher SL, Quinn TP (1997) Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries. J Mol Biol 270:374-384
19. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, Quinn TP (2003) Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 63:3805-3811
20. Nieminen J, Kuno A, Hirabayashi J, Sato S (2007) Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem 282(2):1374-1383. doi: 10.1074/jbc.M604506200
21. Ahmad N, Gabius HJ, Andre S, Kaltner H, Sabesan S, Roy R, Liu B, Macaluso F, Brewer CF (2004) Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 279(12):10841-10847. doi: 10.1074/jbc.M312834200
22. Xie L, Ni WK, Chen XD, Xiao MB, Chen BY, He S, Lu CH, Li XY, Jiang F, Ni RZ (2012) The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol. doi: 10.1007/s00432-012-1178-2
23. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S (2000) Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6:1389-1393
24. Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes JM, Yu LG (2010) Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer 9:154. doi: 10.1186/1476-4598-9-154
25. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563-572. doi: 10.1038/nrc865
26. Fidler IJ (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3(6):453-458. doi: 10.1038/nrc1098
27. Yamamoto N, Yang M, Jiang P, Xu M, Tsuchiya H, Tomita K, Moossa AR, Hoffman RM (2003) Determination of clonality of metastasis by cell-specific color-coded fluorescent-protein imaging. Cancer Res 63(22):7785-7790
28. Crissman JD, Hatfield J, Schaldenbrand M, Sloane BF, Honn KV (1985) Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Lab Invest 53(4):470-478
29. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV (2005) Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 7(5):522-527
30. Platt D, Raz A (1992) Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 84:438-442
31. Inohara H, Raz A (1994) Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11(6):527-532
32. Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI (2003) Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis 6(4):301-304. doi: 10.1038/sj.pcan.4500679
33. Azemar M, Hildenbrand B, Haering B, Heim M, Unger C (2007) Clinical benefit in patients with advanced solid tumors treated with modified citrus pectin: a prospective pilot study. Clin Med: Oncol 1:73-80
34. Seetharaman J, Kanigsberg A, Slaaby R, Leffler H, Barondes SH, Rini JM (1998) X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem 273:13047-13052
35. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, Yagi F, Kasai K (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572(2-3):232-254. doi: S0304416502003112
36. Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ, Glinsky VV (2012) Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine. Neoplasia 14(1):65-73
37. Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49(11):1735-1738. doi: 10.2967/jnumed.108.053041
38. Ochieng J, Furtak V, Lukyanov P (2004) Extracellular functions of galectin-3. Glycoconj J 19(7-9):527-535. doi: 10.1023/B:GLYC.0000014082.99675.2f
39. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T (2005) Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7(4):R444-R454. doi: 10.1186/bcr1026
40. Fidler IJ, Caines S, Dolan Z (1976) Survival of hematogenously disseminated allogeneic tumor cells in athymic nude mice. Transplantation 22(2):208-212
41. Kennel SJ, Lankford TK, Ullrich RL, Jamasbi RJ (1988) Enhancement of lung tumor colony formation by treatment of mice with monoclonal antibodies to pulmonary capillary endothelial cells. Cancer Res 48(17):4964-4968
42. Stackpole CW (1981) Distinct lung-colonizing and lung-metastasizing cell populations in B16 mouse melanoma. Nature 289(5800):798-800
43. Rasband WS (1997-2008) ImageJ. U.S. National Institutes of Health. Available via U.S. National Institutes of Health. http://rsb.info.nih.gov/ij/
44. Disibio G, French SW (2008) Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 132(6):931-939
45. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854-1862
46. Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T, Contag PR (2003) Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 20(8):733-744
47. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, Gerasimenko OV, Hilkens J, Hirabayashi J, Kasai K, Rhodes JM (2007) Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem 282(1):773-781. doi: 10.1074/jbc.M606862200
48. Wong CW, Song C, Grimes MM, Fu W, Dewhirst MW, Muschel RJ, Al-Mehdi AB (2002) Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol 161(3):749-753. doi: 10.1016/S0002-9440(10) 64233-2
49. Boccaccio C, Comoglio PM (2009) Genetic link between cancer and thrombosis. J Clin Oncol 27(29):4827-4833. doi: 10.1200/JCO.2009.22.7199
50. Berny-Lang MA, Aslan JE, Tormoen GW, Patel IA, Bock PE, Gruber A, McCarty OJ (2011) Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol 8(1):015014. doi: 10.1088/1478-3975/8/1/015014
51. Stoffel A (2010) Targeted therapies for solid tumors: current status and future perspectives. BioDrugs 24(5):303-316. doi: 10.2165/11535880-000000000- 00000
52. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86(11):4220-4224
53. Deutscher SL (2010) Phage display in molecular imaging and diagnosis of cancer. Chem Rev 110(5):3196-3211. doi: 10.1021/cr900317f
54. Sun LC, Coy DH (2011) Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 8(1):2-10. doi: BSP/CDD/E-Pub/00052
55. Humphries MJ, Yamada KM, Olden K (1988) Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. J Clin Invest 81(3):782-790. doi: 10.1172/JCI113384
56. Califice S, Castronovo V, Bracke M, van den Brule F (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23(45):7527-7536. doi: 10.1038/sj.onc.1207997